HFSA Heart Failure Seminar: Focus on Devices
Navigating the HF Patient Journey: Devices and New Guidelines

Original Seminar Date:  June 22, 2023
Product Expiration Date: June 26, 2024


Program Overview
The standards, competencies, and clinical data relating to the use of device therapy in heart failure (HF) continue to evolve rapidly. This creates challenges for practicing clinicians trying to stay up-to-date and provide optimum evidence-based care to their patients. Navigating the HF Patient Journey: Devices and New Guidelines will feature a multidisciplinary panel of HF experts presenting a case-based program designed to provide the most current information on the timing selection, and utilization of emerging, novel, and current devices for the management of heart failure. The program will also include information on recently published clinical trials and guidelines on device therapies for HF patients. Among the topics that will be discussed in this program are implantable cardiac defibrillators, cardiac resynchronization therapy (biventricular pacing), monitoring devices, temporary and durable mechanical circulatory support, and devices that reduce heart failure hospitalizations.

This program is intended for cardiologists, interventional cardiologists, primary care physicians, cardiac surgeons, internists, nurse practitioners, physician assistants, nurses, pharmacists, and other health care providers who care for patients with heart failure.

• Welcome Remarks and Introduction
• Introductory Case Study: The Heart Failure Journel
• Device Strategies for Stable HF Patient
• Patients with Worsening HF on GDMT
• Open Discussion
• Patient Presented with Cardiogenic Shock
• Patients on Durable MCS
• Open Discussion

Learning Objectives
1.    Describe the emerging, novel, and current devices for the management of heart failure.
2.    Evaluate the recent updates and guidelines on device therapies for heart failure patients.
3.    Discuss appropriate timing and device selection for temporary mechanical support for patients with heart failure.

• Amin Yehya, MD, MS, FACC, FHFSA – Sentara Healthcare
• Sarah E. Schroeder, PhD, ACNP-NC, MSN, RN – Bryan Health
• Kristen de Almeida, PharmD – Baptist Health 

Faculty Disclosures
The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24 months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity.

Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support.

The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest:

• Kristen de Almeida, PharmD

The following faculty and/or accreditors with ability to control content for this activity have listed the below disclosures:

• Amin Yehya, MD, MS, FACC, FHFSA - Advisory Board: Merck, CareDx, Akcea, Zoll; Speakers Bureau: Merck, CareDx, Akcea, Zoll; Advisor: Lifelink
• Sarah E. Schroeder, PhD, ACNP-NC, MSN, RN - Research Grant: Abbott; Research Study PI: Lincoln Heart and Vascular

Off-Label Disclosure
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

In support of improving patient care, the Heart Failure Society of American is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Heart Failure Society of America designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Successful completion of this CME activity, includes participation in the post-course evaluation.

This educational activity is approved for nursing continuing professional development (NCPD) units by the Heart Failure Society of America. This activity is approved for a maximum of 1.5 contact hours (which inlcudes 1.5 hours of nursing pharmacology).

Pharmacology Hours for Nurses
This educational activity is approved for who require pharmacology hours for their certification or licensure renewal,  This activity is approved for 1.5 pharmacology credits.  Learners should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists



The Heart Failure Society of America is an accredited provider of continuing pharmacy education (CPE). This activity is accredited for 1.5 contact hours of knowledge-based CPE. ACPE Universal Activity Numbers (UAN): JA4008267-0000-23-002-H01-P (Ondemand).

Learners should claim only the credit commensurate with the extent of their participation in the activity.

The Heart Failure Society of America acknowledges the following for providing an unrestricted educational grant to support the Heart Failure Seminar: Focus on Devices: Abbott, Boston Scientific, and CVRx